Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
<p>Shows Phenotype, Viability, and Cytotoxicity of the Product.</p>
Zapisane w:
| 1. autor: | |
|---|---|
| Kolejni autorzy: | , , , , , , , , , , , , |
| Wydane: |
2025
|
| Hasła przedmiotowe: | |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|
| _version_ | 1849927634565201920 |
|---|---|
| author | Ulka N. Vaishampayan (15051039) |
| author2 | Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| author2_role | author author author author author author author author author author author author author |
| author_facet | Ulka N. Vaishampayan (15051039) Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ulka N. Vaishampayan (15051039) Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| dc.date.none.fl_str_mv | 2025-11-25T12:41:15Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30705743 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Table_S2_from_Phase_II_Trial_of_Pembrolizumab_and_Anti-CD3_x_Anti-HER2_Bispecific_Antibody-Armed_Activated_T_Cells_in_Metastatic_Castration-Resistant_Prostate_Cancer/30705743 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |
| dc.title.none.fl_str_mv | Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Shows Phenotype, Viability, and Cytotoxicity of the Product.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_bdc322f2cb39552c8b999a22b29c5a5f |
| identifier_str_mv | 10.1158/1078-0432.30705743 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30705743 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate CancerUlka N. Vaishampayan (15051039)Archana Thakur (15051042)Wei Chen (15051045)Abhinav Deol (15051048)Meera Patel (15051051)Kimberlee Dobson (15051054)Brenda Dickow (15051057)Dana Schalk (15051060)Amy Schienschang (15051063)Sarah Whitaker (15051066)Amanda Polend (15051069)Joseph A. Fontana (411960)Elisabeth I. Heath (15024674)Lawrence G. Lum (15051072)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsPhase II clinical trialsGenitourinary CancersProstate cancerImmunotherapyCellular immunotherapy<p>Shows Phenotype, Viability, and Cytotoxicity of the Product.</p>2025-11-25T12:41:15ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30705743https://figshare.com/articles/figure/Supplementary_Table_S2_from_Phase_II_Trial_of_Pembrolizumab_and_Anti-CD3_x_Anti-HER2_Bispecific_Antibody-Armed_Activated_T_Cells_in_Metastatic_Castration-Resistant_Prostate_Cancer/30705743CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307057432025-11-25T12:41:15Z |
| spellingShingle | Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Ulka N. Vaishampayan (15051039) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |
| status_str | publishedVersion |
| title | Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_full | Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_fullStr | Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_full_unstemmed | Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_short | Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_sort | Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| topic | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |